Physician profile
Ellen Kudrow
NPI 1689054199
$12,394.13
in general payments reported to CMS, 2019-2025
21 companies · $3,344 in 2025
The $3,344 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,912 · 2022: $1,283 · 2023: $2,627 · 2024: $3,229 · 2025: $3,344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,176 · Education: $23.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,175.62 |
| Education | $23.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,118.94 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $2,096.19 | 2021-2025 | |
| Lundbeck LLC | $1,523.22 | 2021-2025 | Abilify Asimtufii, Rexulti, Brintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $921.73 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $754.36 | 2021-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $749.57 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Axsome Therapeutics, INC. | $646.05 | 2023-2025 | Auvelity |
| Alkermes, INC. | $585.77 | 2022-2025 | Lybalvi, Aristada |
| E.R. Squibb & Sons, L.L.C. | $538.66 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $505.84 | 2021-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $464.56 | 2023-2025 | Qelbree, Qelbree |
| Corium, LLC | $399.84 | 2022-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $378.18 | 2021-2025 | Spravato, Invega Sustenna |
| Almatica Pharma LLC | $230.84 | 2023-2024 | Loreev Xr, Gralise |
| Takeda Pharmaceuticals U.S.A., INC. | $167.63 | 2021-2025 | Trintellix |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $125.00 | 2022 | |
| Indivior INC. | $86.87 | 2021-2024 | Sublocade |
| Orexo US, INC. | $41.90 | 2022-2023 | Zubsolv |
| Idorsia Pharmaceuticals US INC | $22.63 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.45 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Kudrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.